Note: ProFocal is not approved in any jurisdiction.
Prostate cancer is the most commonly diagnosed cancer in men, with one in six men receiving a diagnosis during their lifetime. While curative treatments like surgery and radiotherapy are recommended for approximately two-thirds of patients, these options often come with significant side effects – such as urinary incontinence and erectile dysfunction – that can significantly impact quality of life post treatment.
Focal therapy is an emerging and experimental treatment for prostate cancer, the aim of which is to target only cancerous areas within the prostate, preserving surrounding healthy tissue to reduce side effects of treatment.
This approach balances oncologic efficacy with quality-of-life preservation, offering a middle ground between active surveillance and whole-gland treatments. While long-term data is still emerging, early results highlight its potential as a transformative option for eligible patients.